New paths for a bispecific road less traveled 

As bispecifics against two tumor antigens win their first approval and gain traction at ASCO, drug developers are also eyeing the opportunities this class of compounds could open up for ADCs.

Bispecific antibodies are steadily becoming a must-have for cancer drug developers. The modality has surpassed both mAbs and cell therapies as the focus of pharma oncology deals, and has been a consistent bright spot at cancer meetings, generating clinical data in new target spaces of immuno-oncology that CAR Ts haven’t yet touched...